<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences Runs NeuroScientific Study: Publishes Positive Results in Fight Against Alzheimer's

Posted by MD Biosciences on Aug 5, 2019 10:46:44 AM

View Publication Here

Our team of neuroscience specialists ran a preclinical study with NeuroScientific Biopharmaceuticals in hopes of progressing towards a human trial later in the year for Alzheimer's. Using lead drug candidate EmtinB known to stimulate the reformation of the neuronal network and restore function of damaged nerve cells, the nerve cells were successfully able to communicate again in this study. In fact, EmtinB was able to stimulate regeneration of nerve cells by more than 300% compared to the control. This is significant in affecting synapse loss, a key contributor of cognitive impairment. Together, we are paving the way for successful therapeutic treatment options for Alzheimer's. Learn about our neurodegenerative animal models, behavioral assessments and other neuroscience research services here! 

Read More

Topics: CRO/outsourcing, Neuro/CNS, preclinical research, Behavioral Research, Neuroscience, Nerve Injury, Alzheimer's

IHC Staining Image Gallery Now LIVE: High resolution whole slide image samples from in-house histopathology laboratory

Posted by MD Biosciences on Mar 21, 2019 11:57:33 AM

 MD Biosciences has extensive experience in the application of immunohistochemistry to analysis of markers of interest in tissue. Our validated protocols permit such assessments as lymphocyte analysis, cellular proliferation, cellular activation/differentiation, inflammation, biomarker analysis, and much more.

View high-resolution whole slide image examples of our IHC staining results below!



Don't see a marker you're interested in? We provide custom IHC assay development and validation using either commercially available or Sponsor-provided antibodies, and additionally have in-house antibody development facilities for challenging targets. Contact us to discuss a custom project! 

Contact Us Today!  651-641-1770

Read More

Topics: CRO/outsourcing, Biomarkers, Imaging, Pathology, GLP Histopathology, clinical research, Histology, GLP, In-situ Hybridization, Immunohistochemistry, Tissue Processing

MD Biosciences GLP-approved Histopathology Laboratory launches new website: featuring histology, IHC, ISH and digital pathology services

Posted by MD Biosciences on Feb 15, 2019 9:00:00 AM

Our new histopathology website is now live! Check it out here!

MD Biosciences Laboratories offer a broad range of histology, immunohistochemistry (IHC) and In-situ hybridization services, staining services, tissue processing and digital pathology to enhance readouts and study applicability to the clinic.

We operate two distinct histology and IHC laboratories, including a GLP developmental research laboratory and a CLIA clinical IHC laboratory, offering a broad range of state-of-the-art technical capabilities to meet research and clinical study needs. Method development and optimization in addition to routine analysis shapes the foundation for our tissue-based services. The laboratories are equipped with advanced automated staining systems and digitized imaging, facilitating the privileged access to large, annotated image files. Services are complimented by the Visiopharm artificial intelligence-based image analysis platform to enhance the quality and speed of analysis. Services are supported by expert consultant pathologists specialized in various areas. 

Contact us to learn more about our services!

Contact Us

Read More

Topics: CRO/outsourcing, Pathology, GLP Histopathology, Histology, GLP, Artificial Intelligence, In-situ Hybridization, CLIA certified, Immunohistochemistry, Tissue Processing


Posted by MD Biosciences on Apr 20, 2017 3:20:14 PM

Saint Paul, MN, April 20, 2017     Five leading research organizations have partnered to provide the most comprehensive clinical development platform in the industry. Leveraging their collective expertise, the Center for Diagnostic Imaging (CDI), Medtronic, MD Biosciences, Prism Research, and ThreeWire, have come together to make it easier for life science companies and clinicians to bring lifesaving and life improving products to patients in need. Dubbed the Minnesota Clinical Research Hub, this partnership provides sponsors with a flexible platform for conducting their trials, allowing use of the partners individually and collectively as research needs dictate. Contact MD Biosciences for more details about the MCRH and activities.



About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Read More

Topics: CRO/outsourcing, contract research, Personalized medicine, CLIA

MD Biosciences & Janssen R & D, LLC to screen extensive library of compounds.

Posted by MD Biosciences on Apr 14, 2014 9:00:00 AM

MD Biosciences enters into an agreement with Janssen Research & Development, LLC to screen an extensive library of compounds with its proprietary Senerga® Phenotypic Screening Platform.


St Paul, MN (April 14, 2014) – MD Biosciences announces that it has entered into a research agreement with Janssen Research & Development, LLC, through the Janssen Incubator and a venture team focused on natural product drug discovery programs, to screen a novel and proprietary chemical library of compounds for pharmaceutically relevant activity.  MD Biosciences will apply its innovative screening platform, Senerga® Phenotypic Screening Platform for this purpose. Senerga® PSP is based on three matrices covering  pathways related to inflammatory, metabolic, cardiovascular and CNS diseases in addition to delivering preliminary toxicology data. Senerga® PSP delivers a comprehensive portfolio of phenotypic and biomarker data for each compound in the library and points towards putative mode of action of novel compounds. A dedicated scoring algorithm is used to rank compounds with regards to their activity. Pharmaceutically active compounds will be validated in dedicated disease models. The use of Senerga® PSP provides unique speed and efficiency in mining its novel chemical library.


About the Senerga® Screening Platform

MD Biosciences has in-depth expertise and data on complex programs involving mechanism of action and efficacy studies. Senerga®PSP provides a uniquely customized approach applicable to new compounds as well as for repositioning of failed or on-market drugs. Senerga® is available for collaborative development programs together with pharmaceutical and biotechnology companies.


About MD Biosciences

MD Biosciences is dedicated to the preclinical discovery and development of compounds. The company engages in collaborative partnerships and research projects with pharmaceutical and biotechnology companies world wide. MD Biosciences operates purpose-built and state-of-the-art facilities in Nes Ziona, Israel and in St. Paul, MN, USA.





The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: CRO/outsourcing, news

MD Biosciences Receives AAALAC Accreditation

Posted by MD Biosciences on Mar 19, 2014 1:59:00 PM

Wednesday, March 19, 2014, St. Paul, MN – MD Biosciences, a drug discovery and development services provider, is pleased to announce it has been give full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Accreditation for the St Paul facility was awarded following an extensive on-site assessment by representatives of the Council on Accreditation, which stated that MD Biosciences “provides and maintains an excellent program of laboratory animal care and use” with particular noteworthiness in the program alignment with quality animal care and use, comprehensive occupational health and hazard reduction, high level of attention to detail in documentation and standard operating procedures as well as staff training programs and a high level of expertise among the personnel. 


“We are very pleased to receive accreditation from AAALAC, recognizing that only 900+ institutions worldwide carry this accreditation. MD Biosciences prides itself on high standards both in scientific methods and animal care. This accreditation provides our clients assurance of our commitment to compliance with industry and regulatory guidelines for high standards of animal care and handling” said Eddie Moradian, CEO of MD Biosciences. Researchers can read further about the benefits of accreditation here.


MD Biosciences is also committed to its continuing development and expansion of services it offers its clients and partners from its multiple laboratories. In addition to specialized efficacy studies and the development of more clinically relevant models, MD Biosciences also offers its partners customized screening programs aligned with clients’ specific business goals.



 About AAALAC International

AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. AAALAC stands for the "Association for Assessment and Accreditation of Laboratory Animal Care." More than 900 companies, universities, hospitals, government agencies and other research institutions in 37 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use. These institutions volunteer to participate in AAALAC's program, in addition to complying with the local, state and federal laws that regulate animal research.



About MD Biosciences

MD Biosciences is a leading preclinical research group and contract research organization (CRO) working with biopharmaceutical and medical device companies in an effort towards progressing discovery and development programs to clinical stages. We are deeply focused on inflammatory, neurodegenerative/CNS, pain, dermal, metabolic and cardiovascular conditions with a particular emphasis on the interplay between the immune, nervous and cardiovascular systems and the conditions that arise in the cross talk between them. We bring decisive value to our clients’ programs with the extensive experience gained over many years of handling different compound classes and numerous therapeutic indications. MD Biosciences operates three state-of-the-art laboratories across the globe equipped with highly specialized infrastructure, equipment, methods and scientists with expertise in therapeutics areas. Find out more about MD Biosciences and the services offered at www.mdbiosciences.com.




The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: CRO/outsourcing, news

Expansion of the US Preclinical Contract Research Lab

Posted by MD Biosciences on Jun 26, 2013 8:48:00 AM

Additional capacity enables MD Biosciences to increase the existing models as well as continue the development of new methods and biomarkers that help bridge the gap between nonclinical data and clinical outcomes.

MD Biosciences, a global preclinical contract research organization (CRO), announces the expansion of its preclinical contract research laboratory in St Paul, MN. The expansion of the laboratory provides additional capacity to increase the in vivo research models of its existing inflammations division. In addition to inflammations models, expansion into the areas of metabolic and cancer research are underway with metabolic studies already being offered. As part of this expansion, MD Biosciences is also hiring experienced scientists in these areas to join our St Paul research team.

As biopharma companies are dealing with reduced R&D budgets and pressures to replace revenue from patent expirations, bringing a clinical mindset to non-clinical study design assists in reducing late phase failures. MD Biosciences is continually developing new methods that help address the gap between non-clinical data and clinical outcomes. Often times existing preclinical models are all that is available but don’t necessarily reflect what is seen in the clinic – additional capacity enables MD Biosciences to continue its R&D program in search of new and more relevant preclinical models and biomarkers.

MD Biosciences currently offers a wide selection of in vivo models within inflammation/autoimmune, CNS, pain, wound healing and cardiovascular fields of research. Its focus is on the cross-talk between the immune and neural systems and the areas of overlap as well as contributions of one to the other in disease pathways. This deep understanding in the cross-talk and a strict focus on sponsors objectives enables MD Biosciences to contribute to the overall study design.

“The expansion of the preclinical contract research lab in the US assists us in serving both North American and International clients. Our global laboratories in the US, UK and Israel are positioned to be able to serve each market and research niche efficiently with strong scientific insight. Our approach to deeply understand each sponsors objectives allows us to contribute and invest scientifically in their program.” says CEO Eddie Moradian.

About MD Biosciences

MD Biosciences is a global preclinical contract research organization (CRO) specializing in the areas of autoimmune, CNS and cardiovascular. Our focus is not only on the science but also on the understanding of our clients’ objectives. This enables us to partner with our sponsors in the project design phase to ensure that studies accurately address the questions being asked. Research facilities are located in the US, UK and Israel – all strategically located within strong scientific and collaborative networks. The flexible, responsive and collaborative approach with a strong scientific understanding of systems cross-talk offers a unique offering to the biopharma community.


Forward looking statement:

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.


Read More

Topics: CRO/outsourcing

MD Biosciences Expands Pre-clinical Inflammatory & Neuro Drug Research

Posted by Amy Clausen on Oct 5, 2009 11:51:00 AM

MD Biosciences (MDB), a contract research organization offering pre-clinical services and products in support of drug discovery for inflammatory and neurological diseases, relocated its U.S. office from 1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on October 3, 2009. The new location equips MD Biosciences with more lab space, allowing for increased capacity for in vitro services and product development and manufacturing to increase product offering.

Eddie Moradian, President of MD Biosciences states, "At MD Biosciences, we have always promised our clients that we will meet their needs now and in the future; our expansion ensures that commitment. We doubled our lab space so that we are able to provide 150 percent more services and increase product development by 130 percent in the coming year in comparison with the last.

Our relocation is just one step of many in the endeavor to continue to offer the highest quality services and products in assisting our customers in meeting their objectives. Future projections include adding more highly specialized scientists to our team and increasing our focus on our available products and proprietary reagents."

About MD Biosciences

MD Biosciences provides products and pre-clinical services, which include efficacy testing, mode of action platforms, in vitro analysis, histology and imaging for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of experts to tackle problems and provide solutions. MDB also supplies for purchase by all laboratories many of the products and proprietary reagents used in our research, regardless of whether MDB is contracted as a research organization. This allows our clients to optimize their own research process by selecting steps to be performed by MDB and research to be performed in-house.


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Read More

Topics: CRO/outsourcing